Verrica Q3 loss widens to $12.4M as revenue falls
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Verrica Pharmaceuticals Inc. reported Q3 2026 total revenue of $6.914 million, compared with $14.344 million a year earlier, and a net loss of $12.407 million, versus $274,000. U.S. YCANTH net product revenue was a record $5.697 million, up 11.9% from the prior quarter and 57.9% year over year; license and collaboration revenue was $1.217 million, down from $10.737 million. For the first nine months, revenue was $17.799 million versus $30.485 million, and net loss was $35.242 million versus $9.812 million.
The company said it met pre-defined revenue, growth and operational milestones under its credit facility, unlocking full access to $27.5 million of non-dilutive growth capital. Under its current operating plan, including full utilization of the facility, Verrica said it has sufficient liquidity to fund operations through data readouts for both common-warts trials. Enrollment is complete in the first pivotal Phase 3 trial, and the second has enrolled more than 50% of its current patient target; topline data are expected in Q1 2027 and mid-2027, respectively. Verrica is exploring VP-315 for Gorlin syndrome.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointYCANTH product revenue reached $5.697 million, up 57.9% year over year.
Negative
- Moderate pointQ3 total revenue was $6.914 million, versus $14.344 million a year earlier.
- Moderate pointQ3 net loss was $12.407 million, versus $274,000 a year earlier.
Filing Explained
At
8-K Event Classification
Key Figures
Key Terms
net product revenue financial
gross to net financial
non-GAAP income (loss) from operations financial
oncolytic chemotherapeutic peptide immunotherapy medical
immunogenic cell death medical
topline data medical
Earnings Snapshot
Topline data from the first and second common-warts pivotal trials are expected in Q1 2027 and mid-2027, respectively. Verrica said it has sufficient liquidity to fund operations through both readouts under its current operating plan, including full utilization of its credit facility.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much YCANTH revenue did VRCA report in Q3 2026?
Why was enrollment completed in Verrica’s first common-warts pivotal trial?
AI-generated analysis. How Rhea-AI works. Not financial advice.